Tropisetron

Jump to: navigation, search
Tropisetron
Tropisetron2DACS2.png
Tropisetron3Dan.gif
Clinical data
Pregnancy
category
  • AU: X (High risk)
Routes of
administration
Oral, IM
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability~60–80%
Protein binding71%
MetabolismHepatic (CYP3A4, CYP1A2, CYP2D6)
Elimination half-life6–8 hours
ExcretionRenal, Fecal
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC17H20N2O2
Molar mass284.353 g/mol
3D model (JSmol)

WikiDoc Resources for Tropisetron

Articles

Most recent articles on Tropisetron

Most cited articles on Tropisetron

Review articles on Tropisetron

Articles on Tropisetron in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Tropisetron

Images of Tropisetron

Photos of Tropisetron

Podcasts & MP3s on Tropisetron

Videos on Tropisetron

Evidence Based Medicine

Cochrane Collaboration on Tropisetron

Bandolier on Tropisetron

TRIP on Tropisetron

Clinical Trials

Ongoing Trials on Tropisetron at Clinical Trials.gov

Trial results on Tropisetron

Clinical Trials on Tropisetron at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Tropisetron

NICE Guidance on Tropisetron

NHS PRODIGY Guidance

FDA on Tropisetron

CDC on Tropisetron

Books

Books on Tropisetron

News

Tropisetron in the news

Be alerted to news on Tropisetron

News trends on Tropisetron

Commentary

Blogs on Tropisetron

Definitions

Definitions of Tropisetron

Patient Resources / Community

Patient resources on Tropisetron

Discussion groups on Tropisetron

Patient Handouts on Tropisetron

Directions to Hospitals Treating Tropisetron

Risk calculators and risk factors for Tropisetron

Healthcare Provider Resources

Symptoms of Tropisetron

Causes & Risk Factors for Tropisetron

Diagnostic studies for Tropisetron

Treatment of Tropisetron

Continuing Medical Education (CME)

CME Programs on Tropisetron

International

Tropisetron en Espanol

Tropisetron en Francais

Business

Tropisetron in the Marketplace

Patents on Tropisetron

Experimental / Informatics

List of terms related to Tropisetron

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Tropisetron (INN) is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy, although it has been used experimentally as an analgesic in cases of fibromyalgia.[1] The drug is available in a 5 mg oral preparation or in 2 mg intravenous form. It is marketed by Novartis in Europe, Australia and New Zealand as Navoban, but is not available in the U.S.

Adverse effects

Tropisetron is a well-tolerated drug with few side effects. Headache, constipation, and dizziness are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drug's use. It is broken down by the hepatic cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system.

External links

References

  1. Muller, W. (2004). "Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron". Scand J Rheumatic Suppl. 119: 44–48. PMID 15515413. Retrieved 2007-05-17. Unknown parameter |coauthors= ignored (help)

Linked-in.jpg